RESEARCH PIPELINE
FNDR has generated a pipeline of therapeutics in various bacterial, viral, fungal and parasitic indications spanning over early-stage discovery to late-stage clinical trials.
PROJECT DETAILS
TBA-7371
Tuberculosis
Clinical, Phase 2
A DprE1 inhibitor being developed for tuberculosis. The patent is jointly held by TB Alliance and FNDR. Phase 2 Clinical trial is being carried out by Gates Medical Research Institute in South Africa (Trial No. NCT04176250)
FNDR20364
Tuberculosis, NTM, Bacterial Infections
Preclinical, IND Enabling Studies
A novel anti-TB compound extracted from the soil of Antarctica, has shown promising activity against drug resistant TB. FNDR is a patent holder along with National Centre for Polar and Ocean Research, Ministry of Earth Sciences, Government of India. Development for TB is funded by BIRAC. It is also known as NF1001. FNDR20364 has also shown excellent in vitro activity against multiple drug sensitive and drug resistant NTMs and its development for NTMs is funded by the Cystic Fibrosis Foundation (CFF), USA. FNDR20364 also works against drug resistant Gram-postive bacteria.
Chloroquine
Tuberculosis
Preclinical, Repurposed Drug
A well-known clinical candidate repositioned for shortening TB therapy in partnership with Indian Institute of Science (IISc), Bangalore. The project is funded by DBT India.
Amphotericin B (Oral formulation)
Fungal Infections, Leishmania
Repurposed Drug, Preclinical
Liposomal Amphotericin B is an injectable drug for fungal infections and leishmania. FNDR has partnered with AIIMS New Delhi to develop an oral formulation of Amphotericin B and the project is funded by DBT India.
FNDR20123
Malaria
Preclinical, IND Enabling Studies
A novel compound with new mechanism which has shown excellent activity against various malarial strains. IND enabling studies are being planned.
Device for Antibiotic Depletion from Industrial Waste Water/Hospital Effluents
AMR
Validation
FNDR is developing a novel device made of waste materials to remove antibiotics from waste water. Antimicrobial resistance (AMR) is a global threat due to discharge/dumping of antibiotics from industries such as API manufacturing, poultry, fisheries, animal husbandry, and hospitals. Currently there is no device to deplete antibiotics from effluents. The lab scale device is ready and prototype device in development.
Biomarkers To Detect Tuberculosis
Tuberculosis
Proof of Concept
FNDR is developing a blood-based diagnostic for rapid detection of pulmonary and extra-pulmonary tuberculosis. Current biomarker-based tests for Pulmonary TB are low in accuracy or specificity. No tests exist for Extra-pulmonary TB. Clinical trial of 200 patients at St John’s Hospital, Bangalore has been completed to test for biomarkers in blood and urine. Data is promising and indicates potential for a rapid biomarker (blood) based diagnostic which can be converted to a Point of Care Test.
Biomarkers To Differentiate Bacterial Vs Viral Infections
AMR
Proof of Concept
FNDR is developing a blood-based diagnostic for rapid differentiation between bacterial and viral infections to guide antibiotic prescriptions . Antimicrobial resistance (AMR) is a global threat due to misuse of antibiotics. Currently there is no biomarker test on market. Pre-clinical validation has been completed and clinical trial to establish clinical validation is in progress.